News

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

December 7, 2021 (Investorideas.com Newswire) “Solid tumors offers a substantial opportunity for Karyopharm Therapeutics’ Xpovio (selinexor) that perhaps investors have not yet realized,”

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News

Next Article:

0 %